236 related articles for article (PubMed ID: 22139535)
1. Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.
Joung YK; Son S; Jang JY; Kwon MH; Park KD
Pharm Res; 2012 Apr; 29(4):932-42. PubMed ID: 22139535
[TBL] [Abstract][Full Text] [Related]
2. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles.
Son S; Lee WR; Joung YK; Kwon MH; Kim YS; Park KD
Int J Pharm; 2009 Feb; 368(1-2):178-85. PubMed ID: 18996459
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
Xin L; Zhang HT; Yang WF; Li YF; Liu C
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
[TBL] [Abstract][Full Text] [Related]
4. Functional stability of 3D8 scFv, a nucleic acid-hydrolyzing single chain antibody, under different biochemical and physical conditions.
Lee J; Park H; Kim M; Seo Y; Lee Y; Byun SJ; Lee S; Kwon MH
Int J Pharm; 2015 Dec; 496(2):561-70. PubMed ID: 26536531
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors.
Bhatnagar P; Kumari M; Pahuja R; Pant AB; Shukla Y; Kumar P; Gupta KC
Drug Deliv Transl Res; 2018 Jun; 8(3):565-579. PubMed ID: 29441466
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
[TBL] [Abstract][Full Text] [Related]
7. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.
Nair K L; Jagadeeshan S; Nair SA; Kumar GS
Int J Nanomedicine; 2011; 6():1685-97. PubMed ID: 21980233
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery.
Vasconcelos A; Vega E; Pérez Y; Gómara MJ; García ML; Haro I
Int J Nanomedicine; 2015; 10():609-31. PubMed ID: 25670897
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin.
Yang T; Nyiawung D; Silber A; Hao J; Lai L; Bai S
AAPS PharmSciTech; 2012 Dec; 13(4):1309-18. PubMed ID: 23054983
[TBL] [Abstract][Full Text] [Related]
10. Spermidine-mediated poly(lactic-
Tang J; Li J; Li G; Zhang H; Wang L; Li D; Ding J
Int J Nanomedicine; 2017; 12():6687-6704. PubMed ID: 28932114
[TBL] [Abstract][Full Text] [Related]
11. Small molecule delivery to solid tumors with chitosan-coated PLGA particles: A lesson learned from comparative imaging.
Park J; Pei Y; Hyun H; Castanares MA; Collins DS; Yeo Y
J Control Release; 2017 Dec; 268():407-415. PubMed ID: 29111150
[TBL] [Abstract][Full Text] [Related]
12. Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.
Dyawanapelly S; Koli U; Dharamdasani V; Jain R; Dandekar P
Drug Deliv Transl Res; 2016 Aug; 6(4):365-79. PubMed ID: 27106502
[TBL] [Abstract][Full Text] [Related]
13. Micelle-templated, poly(lactic-
Nabar GM; Mahajan KD; Calhoun MA; Duong AD; Souva MS; Xu J; Czeisler C; Puduvalli VK; Otero JJ; Wyslouzil BE; Winter JO
Int J Nanomedicine; 2018; 13():351-366. PubMed ID: 29391794
[TBL] [Abstract][Full Text] [Related]
14. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
15. A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and C57BL/6 mice.
Lee G; Yu J; Cho S; Byun SJ; Kim DH; Lee TK; Kwon MH; Lee S
PLoS Pathog; 2014 Jun; 10(6):e1004208. PubMed ID: 24968358
[TBL] [Abstract][Full Text] [Related]
16. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D
Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709
[TBL] [Abstract][Full Text] [Related]
17. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited.
Xu P; Gullotti E; Tong L; Highley CB; Errabelli DR; Hasan T; Cheng JX; Kohane DS; Yeo Y
Mol Pharm; 2009; 6(1):190-201. PubMed ID: 19035785
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel coumarin-triazole hybrids and first evaluation of the 4-phenyl substituted hybrid loaded PLGA nanoparticles delivery system to the anticancer activity.
Arvas B; Ucar B; Acar T; Varli HS; Arvas MB; Aydogan F; Yolacan C
Nanotechnology; 2024 May; 35(30):. PubMed ID: 38636487
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
